Shao, Lipei
Pelayo, Alejandra
Shi, Rongye
Ma, Jinxia
Liu, Hui
Cai, Yihua
Prochazkova, Michaela
Somerville, Robert P.
Panch, Sandhya R.
Shah, Nirali N.
Stroncek, David F.
Jin, Ping
Funding for this research was provided by:
Foundation for the National Institutes of Health
National Institutes of Health
Article History
Received: 7 July 2022
Accepted: 11 July 2022
First Online: 28 July 2022
Declarations
:
: The CD22 CAR T-cell products in clinical trial was approved by the National Cancer Institute Institutional Review Board. Products that were analyzed were from patients who consented to additional genomic testing and were enrolled on a companion study for study of biologic correlatives (Clinicaltrials.gov NCT01109394).
: Not applicable.
: Authors declare no competing interests.